Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003)

Journal of Psychopharmacology

Volumn 20, Issue 3, 2006, Pages 456-463

  Schifano, Fabrizio ^a   Corkery, John ^a   Deluca, Paolo ^a   Oyefeso, Adenekan ^a   Ghodse, A Hamid ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Ecstasy deaths; Ecstasy offenders; Ecstasy prevalence of use; Ecstasy price; Ecstasy seizures; MDMA

Indexed keywords

2 METHYLAMINO 1 (3 4 METHYLENEDIOXYPHENYL)BUTANE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; UNCLASSIFIED DRUG;

ARTICLE; CAUSE OF DEATH; CRIME; DEATH; DEATH CERTIFICATE; DRUG ABUSE; DRUG USE; FORENSIC SCIENCE; HEALTH SURVEY; MORTALITY; OFFENDER; PREVALENCE; PRIORITY JOURNAL; REGISTER; SEIZURE; STATISTICAL SIGNIFICANCE; STATISTICS; TABLET; UNITED KINGDOM;

3,4-METHYLENEDIOXYAMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; CAUSE OF DEATH; CRIME; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG AND NARCOTIC CONTROL; GREAT BRITAIN; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; STATISTICS; STREET DRUGS;

EID: 33645730370     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106060147     Document Type: Article

References (45)

1. Ahmad M, Mwenda L (2004) Drug seizure and offender statistics, United Kingdom, 2001 and 2002. In Statistical Bulletin 8/04. Home Office Research Development and Statistics Directorate, London
2. Aust R, Sharp C, Goulden C (2002) Prevalence of drug use. In Key Findings from the 2001/2 British Crime Survey. Findings 182. Home Office Research Development and Statistics Directorate, London
3. Bellis M A, Hughes K, Bennett A, Thomson R (2003) The role of an international nightlife resort in the proliferation of recreational drugs. Addiction 98: 1713-1721
4. Bellis M A, Morleo M, Hughes S, McVeigh J, Lodwick A, Eaton G, Donnelly S (2004) Report to the EMCDDA by the Reitox National Focal Point. United Kingdom Drug Situation 2002. Department of Health, London
5. Bramley-Harker E (2001) Sizing the UK market for illicit drugs. RDS Occasional Paper No 74. Home Office Research Development and Statistics Directorate, London
6. Budisavljevic M N, Stewart L, Sahn S A, Ploth D W (2003) Hyponatremia associated with 3,4-methylenedioxymethylamphetamine ('Ecstasy') abuse. Am J Med Sci 326: 89-93
7. Christophersen O, Rooney C, Kelly S (1998) Drug-related Mortality: Methods and Trends. Population Trends No 93, Autumn 1998. Office for National Statistics, London
8. Cole J C, Bailey M, Sumnall H R, Wagstaff G F, King L A (2002) The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97: 1531-1536
9. Corapcioglu A, Ogel K (2004) Factors associated with Ecstasy use in Turkish students. Addiction 99: 67-76
10. Corkery J M (2002) Drug seizure and offender statistics, United Kingdom, 2000, Home Office Statistical Bulletin 4/02. Home Office Research, Development and Statistics Directorate, London
11. de la Torre R, Farre' M, Roset P N, Hernandez Lopez C, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, Cami J (2000) Pharmacology of MDMA in humans. Ann NY Acad Sci 914: 225-237
12. European Monitoring Centre for Drugs and Drug Addiction; EMCDDA (2004) The state of the drugs problem in the European Union and Norway. Office for Official Publications of the European Communities, Luxembourg
13. Fallon J K, Shah D, Kicman A T, Hutt A J, Henry J A, Cowan D A, Forsling M (2002) Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci 965: 399-409
14. Forsling M L, Fallon J K, Shah D, Tilbrook G S, Cowan D A, Kicman A T, Hutt A J (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135: 649-656
15. Forensic Science Service (2003) Drug Abuse Trends, publication 1994-2003. Issues 103-113 (Old Series) and Issues 1-27 (New Series). Drugs Intelligence Unit, Forensic Science Service, Birmingham
16. Ghodse A H, Schifano F, Oyefeso A, Bannister D, Cobain K, Dryden R, Corkery J (2004) Drug-related deaths as reported by participating Procurators Fiscal and coroners in England, Wales, Northern Ireland, Scotland, Isle of Man, Guernsey and Jersey. Annual report 2004 and Surveillance Report No. 13. International Centre for Drug Policy, St George's Hospital Medical School, London
17. Gilhooly T C, Daly A K (2002) CYP2D6 deficiency, a factor in ecstasy related deaths? Br J Clin Pharmacol 54: 69-70
18. Griffiths C (2004) Deaths related to drug poisoning: England and Wales, 1998-2002. Hlth Stat Quart 21: 59-66
19. Helmlin H J, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R (1996) Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 20: 432-440
20. Henry J A, Jefferys K J, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 340: 384-387
21. Hunt N (2003) Ecstasy deaths. Did alcohol play a part? BMJ.com; Available from: http://bmj.bmjjournals.com/cgi/eletters/326/7380/80
22. Jackson GWL (2004) Drug-related Deaths in Scotland in 2003. Occasional Paper. General Register Office for Scotland, Edinburgh
23. Landry M J (2002) MDMA: a review of epidemiological data. J Psychoactive Drugs 34: 163-169
24. Measham F, Aldridge J, Parker H (2001) Dancing on drugs: risk, health and hedonism in the British club scene. Free Association Books, London
25. National Crime Intelligence Service (2002) Streetwise publication 1994-2002. National Criminal Intelligence Service, London
26. Parr M J, Low H M, Botterill P (1997) Hyponatraemia and death after 'ecstasy' ingestion. Med J Aust 166: 136-137
27. Parrott A C (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol Clin Exp 16: 557-577
28. Parrot A C (2002) Recreational Ecstasy/MDMA, the serotinin syndrome, and serotinergic neurotoxicity. Pharmacol Biochem Behav 71: 837-844
29. Parrott A C (2004) Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology 173: 234-241
30. Patel M M, Wright D W, Ratcliff J J, Miller M A (2004) Shedding new light on the 'safe' club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med 11: 208-210
31. Ramamoorthy Y, Yu A M, Suh N, Haining R L, Tyndale R F, Sellers E M (2002) Reduced (+/-)-3,4-methylenedioxymethamphetamine ('Ecstasy') metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 63: 2111-2119
32. Ramsay M, Baker P, Goulden C, Sharp C, Sondhi A (2001) Drug misuse declared in 2000: results from the British Crime Survey. Home Office Research Study 224. Home Office Research Development and Statistics Directorate, London
33. Sanjurjo E, Nogue S, Miro O, Munne P (2004) Analysis of patients attended in an emergency department due to ecstasy consumption. Med Clin (Barc) 123: 90-92
34. Schifano F (2000) Potential human neurotoxicity of MDMA ('Ecstasy'): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42: 25-33
35. Schifano F (2001) New trends in drug addiction: synthetic drugs; epidemiological, clinical and preventative issues. Epidemiol Psich Soc 10: 63-70
36. Schifano F (2004) A bitter pill? Overview of ecstasy (MDMA: MDA) related fatalities. Psychopharmacol (Berl) 173: 242-248
37. Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse A (2003a) Review of deaths related to taking ecstasy, England and Wales, 1997-2000. Br Med J 326: 80-81
38. Schifano F, Oyefeso A, Corkery J, Cobain K, Jambert-Gray R, Martinotti G, Ghodse AH (2003b) Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. Hum Psychopharmacol Clin Exp 18: 519-524
39. Segura M, Ortuno J, Farre M, McLure J A, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset P N, Segura J, de La Torre R (2001) 3,4- Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14: 1203-1208
40. Sumnall H R, Tyler E, Wagstaff G F, Cole J C (2004) A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers. Drug Alcohol Depend 76: 93-99
41. Topp L, Breen C, Kaye S, Darke S (2004) Adapting the Illicit Drug Reporting System (IDRS) to examine the feasibility of monitoring trends in the markets for 'party drugs'. Drug Alcohol Depend 73: 189-197
42. Tucker G T, Lennard M S, Ellis S W, Woods H F, Cho A K, Lin L Y, Hiratsuka A, Schmitz D A, Chu T Y (1994) The demethylenation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47: 1151-1156
43. Wilkins C, Bhatta K, Pledger M, Casswell S (2003) Ecstasy use in New Zealand: findings from the 1998 and 2001 National Drug Surveys. N Z Med J 116: U383
44. Yacoubian G S Jr (2003) Tracking ecstasy trends in the United States with data from three national drug surveillance systems. J Drug Ed 33: 245-258
45. Zhu B T (2002) Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 3: 321-349